October 26 Earnings: Gilead - Flying the Kite
Gilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform.
The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA.
Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance.
Generic competition will continue to weigh, however, and limit some blockbuster drug expansion.
I'm starting Gilead with a $90 PT for an extended post-earnings move.
A S/L at $75 around recent area is advised.
The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA.
Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance.
Generic competition will continue to weigh, however, and limit some blockbuster drug expansion.
I'm starting Gilead with a $90 PT for an extended post-earnings move.
A S/L at $75 around recent area is advised.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.